Interpreting Milestones: Prioritizing the Patient Picture

Panelists discuss how mutation analysis should be considered when treatment fails to meet milestones or patients show loss of response to tyrosine kinase inhibitor (TKI) therapy, as this information helps determine whether to continue the current TKI or switch to an alternative agent based on the specific resistance profile.

EP: 1.Evaluating Early Treatment Response in CML: Expert Insights on Monitoring

Now Viewing

EP: 2.Interpreting Milestones: Prioritizing the Patient Picture

Video content above is prompted by the following:

• If milestones are not reached, how do you determine whether to switch therapy or continue the current tyrosine kinase inhibitor?
• In what scenarios are you sending a BCR::ABL1 kinase domain mutation result for analysis?

Related Videos